Attached files
| file | filename |
|---|---|
| EX-4.3 - EX-4.3 - MARINUS PHARMACEUTICALS INC | mrns-20201231xex4d3.htm |
| EX-32.1 - EX-32.1 - MARINUS PHARMACEUTICALS INC | mrns-20201231xex32d1.htm |
| EX-31.2 - EX-31.2 - MARINUS PHARMACEUTICALS INC | mrns-20201231xex31d2.htm |
| EX-31.1 - EX-31.1 - MARINUS PHARMACEUTICALS INC | mrns-20201231xex31d1.htm |
| EX-23.2 - EX-23.2 - MARINUS PHARMACEUTICALS INC | mrns-20201231xex23d2.htm |
| EX-21 - EX-21 - MARINUS PHARMACEUTICALS INC | mrns-20201231xex21.htm |
| EX-10.22 - EX-10.22 - MARINUS PHARMACEUTICALS INC | mrns-20201231xex10d22.htm |
| EX-10.9 - EX-10.9 - MARINUS PHARMACEUTICALS INC | mrns-20201231xex10d9.htm |
| EX-10.4 - EX-10.4 - MARINUS PHARMACEUTICALS INC | mrns-20201231xex10d4.htm |
| EX-10.3 - EX-10.3 - MARINUS PHARMACEUTICALS INC | mrns-20201231xex10d3.htm |
| 10-K - 10-K - MARINUS PHARMACEUTICALS INC | mrns-20201231x10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
| 1. | Registration Statement (Form S-3 No. 333-239780) of Marinus Pharmaceuticals, Inc.; |
| 2. | Registration Statement (Form S-3 No. 333-237903) of Marinus Pharmaceuticals, Inc.; |
| 3. | Registration Statement (Form S-8 No. 333-239785) pertaining to the Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended, and Individual Nonqualified Stock Option Awards; |
| 4. | Registration Statement (Form S-8 No. 333-233131) pertaining to the Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended, and Individual Nonqualified Stock Option Awards; |
| 5. | Registration Statement (Form S-8 No. 333-219613) pertaining to the Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan; and |
| 6. | Registration Statement (Form S-8 No. 333-200701) pertaining to the Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan; |
of our report dated March 9, 2021, with respect to the financial statements of Marinus Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Marinus Pharmaceuticals, Inc. for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Philadelphia, PA
March 9, 2021